Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Anaptys (Nasdaq: ANAB) announced that Daniel Faga, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.
A live webcast will be available on the company's investor site at https://ir.anaptysbio.com/presentations-and-events, with a replay available for at least 30 days after the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ANAB fell 3.89% while several biotech peers like KROS (-3.4%), PVLA (-11.9%) and IMTX (-6.7%) were also down, though IKNA rose 3.62%, suggesting mixed stock-specific moves rather than a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Regulatory submission | Positive | +1.4% | BLA submission to FDA supported by positive Phase 3 data. |
| Nov 25 | Investor conferences | Neutral | +1.6% | Announcement of participation in multiple December investor conferences. |
| Nov 21 | Buyback expansion | Positive | +5.2% | Amended <b>$100.0 million</b> repurchase plan and cash outlook update. |
| Nov 21 | Litigation update | Neutral | +5.2% | Initiation of litigation against Tesaro, a GSK subsidiary. |
| Nov 10 | Clinical trial data | Negative | -14.3% | Phase 2 rosnilimab UC trial failed endpoints; trial discontinued. |
Recent moves generally aligned with news tone, including a sharp selloff on negative trial data and a strong gain on the buyback announcement.
Over the past few months, ANAB events have ranged from strategic and financial updates to clinical outcomes. A Nov 10, 2025 release reported a Phase 2 failure in ulcerative colitis with a -14.3% reaction. On Nov 21, 2025, a $100.0 million repurchase expansion coincided with a 5.18% gain. The company has also highlighted potential corporate separation and active investor communications via presentations and conferences. Today’s J.P. Morgan conference appearance fits this pattern of ongoing investor outreach rather than a discrete financial or clinical catalyst.
Market Pulse Summary
This announcement reflects ANAB’s continued engagement with the investment community via a J.P. Morgan Healthcare Conference presentation on Jan 13, 2026, with a webcast and 30-day replay. Recent history included a failed Phase 2 UC trial with a sharp selloff and a sizable stock repurchase expansion linked to a positive reaction. Investors may watch for any new strategic, clinical, or financial details shared at the conference compared with prior disclosures.
AI-generated analysis. Not financial advice.
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.
A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. A replay of the webcast will be available for at least 30 days following the event.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company’s pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease with plans to expand development into an additional indication; and ANB101, a BDCA2 modulator, in a Phase 1a trial. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more here.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When will Anaptys (ANAB) present at the J.P. Morgan Healthcare Conference?
Who from Anaptys (ANAB) is presenting at the Jan 13, 2026 JP Morgan conference?
Where can investors watch the Anaptys (ANAB) webcast for the Jan 13, 2026 presentation?
Will there be a replay of the Anaptys (ANAB) January 13, 2026 presentation?
What topics will Anaptys (ANAB) cover at the 44th Annual J.P. Morgan Healthcare Conference?
How can I access materials or the webcast recording from Anaptys (ANAB) after the JP Morgan presentation?
